PMC5914115_01
Liver MRI showing the segment III lesion, enhancing at the arterial phase (a) with rapid washout on the portal phase (b).
CRIS2018-9183717.001.jpg
PMC5914115_01_CRIS2018-9183717.001.jpg
fig1
C and tumor markers, including alpha-fetoprotein (AFP) and CA19.9, were negative. Contrast-enhanced liver MRI showed a 46 mm tumor in segment III with arterial wash in and portal phase washout (Figures 1(a) and 1(b)).
FDG PET-CT showing the hypermetabolic segment III liver lesion (SUV max: 7.3).
CRIS2018-9183717.002.jpg
PMC5914115_01_CRIS2018-9183717.002.jpg
fig2
A FDG PET scan showed a hypermetabolic liver tumor in segment III, without extrahepatic lesion (Figure 2).
(a) Lymphoid infiltration (bluish discoloration) in hepatocellular parenchyma and (b) germinal center (x100).
CRIS2018-9183717.003.jpg
PMC5914115_01_CRIS2018-9183717.003.jpg
fig3
Pathological examination demonstrated the diagnosis of MALT lymphoma (Figures 3(a) and 3(b)).
Lymphoepithelial complex in hematoxylin eosin stain (x200) (a) and CD20 staining (x400) (b).
CRIS2018-9183717.004.jpg
PMC5914115_01_CRIS2018-9183717.004.jpg
fig4
Small-to-middle-sized lymphocytes formed lymphoepithelial lesions on some bile capillaries (Figure 4(a)). Immunohistochemical stains were positive for CD20 (++) (Figure 4(b)), CD3 (+), CD5 (+), CD43 (+), CD10 (+), Ki67 (10%) anti BCL-6 (+), MUM-1 (+), and CD138 (+), whereas they were negative for CD1.